Incidence and predictors of phantom shocks in implantable cardioverter defibrillator recipients

Netherlands Heart Journal

Volumn 21, Issue 4, 2013, Pages 191-195

  Kraaier, K ^a   Starrenburg, A H ^a   Verheggen, R M ^a   van der Palen, J ^a,b   Scholten, M F ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Implantable defibrillator; Phantom shock; Primary prevention; Psychological consequences; Secondary prevention

Indexed keywords

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IATROGENIC DISEASE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHANTOM SHOCK;

EID: 84878773374     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-012-0345-z     Document Type: Article

References (14)

1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
2. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41(9):1573-82.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37.
4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhyth-mias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-484.
5. van Welsenes GH, Borleffs CJ, van Rees JB, et al. Improvements in 25 years of implantable cardioverter defibrillator therapy. Neth Heart J. 2011;19(1):24-30.
6. Kowey PR, Marinchak RA, Rials SJ. Things that go bang in the night. N Engl J Med. 1992;327(26):1884.
7. Swygman CA, Link M, Cliff D, et al. Incidence of phantom shocks in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 1998;21:810. Ref Type: Abstract.
8. Wojcicka M, Lewandowski M, Smolis-Bak E, et al. Psychological and clinical problems in young adults with implantable cardioverter-defibrillators. Kardiol Pol. 2008;66(10):1050-8.
9. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular tachy-cardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J. 1992;124(2):381-6.
10. Kang Y. Relation of atrial arrhythmia-related symptoms to health-related quality of life in patients with newly diagnosed atrial fibrillation: a community hospital-based cohort. Heart Lung. 2006;35(3):170-7.
11. Prudente LA, Reigle J, Bourguignon C, et al. Psychological indices and phantom shocks in patients with ICD. J Interv Card Electro-physiol. 2006;15(3):185-90.
12. van den Broek KC, Nyklicek I, van der Voort PH, et al. Shocks, personality, and anxiety in patients with an implantable defibrillator. Pacing Clin Electrophysiol. 2008;31(7):850-7.
13. Jacob S, Panaich SS, Zalawadiya SK, et al. Phantom shocks unmasked: clinical data and proposed mechanism of memory reactivation of past traumatic shocks in patients with implantable cardioverter defibrillators. J Interv Card Electrophysiol. 2012;34 (2):205-13.
14. Erdman RA, Pedersen SS. Clinical and scientific progress related to the interface between cardiology and psychology: lessons learned from 35 years of experience at the Thoraxcenter of the Erasmus Medical Center in Rotterdam. Neth Heart J. 2011;19 (11):470-6.